

1 Interpretative summary: Screening for potential probiotic properties of lactic acid  
2 bacteria isolated from kefir grains

3 Leite

4 Lactic acid bacteria and their metabolites may exert beneficial effects on human  
5 health from the consumption of food containing these microorganisms, known as  
6 probiotic. Kefir is a functional dairy beverage and can be an interesting source for the  
7 isolation of microorganisms with probiotic properties. In this study, the potential  
8 probiotic of lactic acid bacteria isolated from different kefir grains was investigated.  
9 A *Lactobacillus paracasei* strain was selected as appropriate probiotic candidate for  
10 potential use in new functional fermented products based on its in vitro tolerance to  
11 gastrointestinal conditions, epithelial adhesion, antimicrobial and antioxidative  
12 activities, besides the absence of undesirable properties.

#### 13 PROBIOTIC PROPERTIES OF LAB FROM KEFIR GRAINS

#### 14 **Probiotic potential of selected lactic acid bacteria strains isolated from Brazilian** 15 **kefir grains**

16 **A.M.O. Leite<sup>\*†‡</sup>; M.A.L. Miguel<sup>§</sup>; R.S. Peixoto<sup>§</sup>; P. Ruas-Madiedo<sup>†</sup>; V.M.F.**  
17 **Paschoalin<sup>†1</sup>; B. Mayo<sup>†</sup>; S. Delgado<sup>†</sup>**

18 <sup>\*</sup>Curso Farmácia, Universidade Federal do Rio de Janeiro - Campus Macaé, Macaé,  
19 RJ, Brazil 27930-560

20 <sup>†</sup>Instituto de Productos Lácteos de Asturias (IPLA-CSIC), Villaviciosa, Asturias,  
21 Spain 33300

22 <sup>‡</sup>Instituto de Química, and

23 <sup>§</sup>Instituto de Microbiologia Paulo de Goes, Universidade Federal do Rio de Janeiro,  
24 Rio de Janeiro, RJ, Brazil 21941-904

25 <sup>1</sup>Corresponding author: Vania Margaret Flosi Paschoalin, Universidade Federal do  
26 Rio de Janeiro, Instituto de Química, Departamento de Bioquímica, Avenida Athos da  
27 Silveira Ramos, 149- CT, Bloco A, Sala 545. CEP: 21941-909 - Cidade Universitária  
28 Rio de Janeiro, RJ, Brazil. Phone: +55 21 39387362, Fax number: +55 21 39387366.  
29 e-mail: paschv@iq.ufrj.br

### 30 **ABSTRACT**

31 A total of 34 lactic acid bacteria (LAB) isolates from four different Brazilian kefir  
32 grains were identified and characterized among a group of 150 isolates, using the  
33 ability to grow at acidic pH and resistance to bile salts as restrictive criteria for  
34 probiotic potential. All isolates were identified by amplified ribosomal DNA  
35 restriction analysis (ARDRA) and 16S rDNA sequencing of representative amplicons.  
36 Eighteen isolates belonged to the species *Leuconostoc mesenteroides*, 11 to  
37 *Lactococcus lactis* (of which eight belonged to the subsp. *cremoris* and three to the  
38 subsp. *lactis*) and five to *Lactobacillus paracasei*. In order to exclude replicates, a  
39 molecular typing analysis was performed by combining rep-PCR and RAPD  
40 techniques. Considering a threshold of 90% similarity, 32 different strains were  
41 considered. All strains showed some antagonistic activity against four model food  
42 pathogens. In addition, three *Lc. lactis* strains and one *Lb. paracasei* produced  
43 bacteriocin-like inhibitory substances against at least two indicator organisms.  
44 Moreover, one *Lc. lactis* and two *Lb. paracasei* presented good total antioxidative  
45 activity. None of these strains showed undesirable enzymatic or haemolytic activities,  
46 while proving susceptible or intrinsically resistant to a series of clinically relevant  
47 antibiotics. The *Lb. paracasei* strain MRS59 showed a level of adhesion to human  
48 Caco-2 epithelial cells comparable to that observed for *Lactobacillus rhamnosus* GG.

49 Taken together, these properties allow the MRS59 strain to be considered a promising  
50 probiotic candidate.

51 **Key Words:** kefir grain, lactic acid bacteria, lactobacilli, probiotic property

## 52 INTRODUCTION

53 Kefir is a fermented milk product originating from the Northern Caucasus. The  
54 name kefir is derived from the Turkish language word “keyif”, meaning “good  
55 feeling” after the feelings experienced after drinking it (Leite et al., 2013a). The  
56 fermented beverage is acidic, viscous, slightly carbonated and presents small amounts  
57 of alcohol (Leite et al., 2013b). Traditionally, kefir is made by using kefir grains as a  
58 starter (Leite et al., 2013a,b). Kefir grains are white to yellowish, cauliflower-like,  
59 grains, 0.3 - 3.5 cm in diameter, with a slimy but firm texture. The grains are  
60 composed of an inert matrix made up of polysaccharides and proteins. The matrix is  
61 densely populated by lactic acid bacteria (**LAB**) species, acetic acid bacteria (**AAB**)  
62 and yeasts (Leite et al., 2012; Leite et al., 2013a).

63 Kefir beverage has a long tradition of consumption in Eastern Europe, and it is  
64 nowadays spreading around the world due to its potential health-associated properties.  
65 Although for some of the health benefits reported there is not yet well documented  
66 scientific evidence or clinical demonstration, several *in vitro* and animal studies have  
67 associated kefir beverage with alleviation of lactose intolerance (Hertzler and Clancy,  
68 2003), immunomodulation (Hong et al., 2009), antimicrobial activity against  
69 pathogenic microorganisms (Chifiriuc et al., 2011) and balance of the intestinal  
70 microbiota (Urdaneta et al., 2007). Traditionally, the functional properties of kefir  
71 have been attributed mainly to its bioactive peptide content and to kefiran, its main  
72 soluble exopolysaccharidic component (Santos et al., 2003; Rodrigues et al., 2005).  
73 However, the potential beneficial effects might also be mediated by the undefined

74 microbial composition of this fermented milk or by their secondary metabolites  
75 (Nielsen et al., 2014).

76 Although there is a reasonable number of well-characterized probiotic strains  
77 commercially available around the world, screening for novel strains is still of great  
78 interest from the industrial points of view (Vinderola et al., 2008; Ayeni et al., 2011).  
79 Additionally, strain expressing unique and particular characteristics that may enable  
80 health benefit may arise in the characterization of natural fermented dairy products  
81 such as kefir. This traditional product might be an interesting source of LAB strain  
82 with specific functional properties. In fact, previous reports described the evaluation  
83 and selection of kefir LAB isolates for potential use as probiotics (Golowczyc et al.,  
84 2008; Zanirati et al., 2014).

85 The aim of the present study was to identify and characterize LAB strains isolated  
86 from traditional kefir grains, displaying *in vitro* properties related to their probiotic  
87 potential according to the guidelines recommended by FAO/WHO (2006). After a  
88 complete characterization and the corresponding *in vivo* trials, these strains could be  
89 ultimately included as probiotics in functional foods.

## 90 MATERIAL AND METHODS

### 91 *Isolation of bacteria from kefir grains*

92 LAB were isolated by dilution and plating from four kefir grains collected in  
93 different regions of Brazil (AR - Niterói, RJ, AD - Lavras, MG, AV - Viçosa, RJ and  
94 AF - Alfenas, MG). Briefly, 10 g of each kefir sample were homogenized in 90 mL of  
95 sodium citrate (2%). Serial decimal dilutions were obtained and plated on lactobacilli  
96 Man, Rogosa, and Sharpe (MRS) and M17 agar media (Difco, Sparks, MD, USA)  
97 supplemented with 200 µg/mL cycloheximide (Sigma-Aldrich, St. Louis, MO, USA),  
98 and incubated in aerobic and anaerobic (Gaspak EZ; Difco) conditions at 30°C for 72

99 h. Representative colonies of all morphologies were taken randomly and purified on  
100 the same media by subculturing. Gram-positive, catalase negative isolates were  
101 considered as presumptive LAB, which were stored in 15% glycerol at  $-80^{\circ}\text{C}$ .

102 For all subsequent assays, LAB were activated in the corresponding media at  $30^{\circ}\text{C}$   
103 for 18-24 h, and subcultured in the same conditions.

#### 104 ***Growth of the isolates at low pH***

105 The ability of the isolates to grow at low pH was assayed as described by Nishida  
106 et al. (2008) in MRS-THIO broth (MRS supplemented with 0.2% sodium  
107 thioglycolate). In short, overnight cultures, corresponding with an initial bacterial  
108 population ranging from  $10^7$  to  $10^9$  cfu/mL, were harvested by centrifugation and cells  
109 were suspended in phosphate-saline-buffer (PBS, pH 6.5) to obtain an  $\text{OD}_{600} = 0.5$ .  
110 Cell suspensions were ten-fold diluted with MRS medium, adjusted to pH 3.0 with  
111 HCl and incubated at  $37^{\circ}\text{C}$  for 3 h. The pH tolerance of the cells was determined by  
112 enumerating the viable cells on MRS agar plates. Non-treated cultures used as  
113 controls were suspended in conventional, non-acidified MRS (pH 6.5).

#### 114 ***Bile tolerance of the isolates***

115 Tolerance to bovine bile (Oxgall; Difco) was assayed by growing the isolates in  
116 agar plates and broth, following the procedure reported by Delgado et al. (2007) and  
117 Guo et al. (2009), respectively. The growth rate of the strains was estimated in MRS-  
118 THIO broth in the absence (control) and in the presence (test) of 0.3% Oxgall.  
119 Overnight cultures were inoculated (1%) into the liquid medium, and cultured at  $37^{\circ}\text{C}$   
120 for up to 9 h. Absorbance at 620 nm was measured every hour. The effect of the bile  
121 salts was scored as the time difference required to increase 0.3 units the absorbance of  
122 the culture at 620 nm ( $\text{OD}_{620}$ ) in MRS-THIO broth with and without 0.3% bile salts.

123 The growth delay (hours) between the culture media was considered as the lag time  
124 (**LT**).

125 Additionally, tolerance of strains to different concentrations of bile salts was  
126 assayed by a plate assay. Individual colonies growing in MRS agar plates were  
127 suspended in 2-5 mL of sterile saline solution 0.85% at a density corresponding to  
128 McFarland standard 1. Aliquots of the suspensions (10 µL) were spotted onto bile-  
129 containing 0.3%, 0.5%, 1% and 2% (w/v) agar plates. The plates were incubated at  
130 37°C under anaerobic conditions and growth was recorded after 24-48 h. A plate  
131 without bile was used as positive control. The experiments were performed in  
132 duplicate.

### 133 *Identification of LAB isolates*

134 Total genomic DNA of the isolates was extracted using the GenElute Bacterial  
135 Genomic DNA kit (Sigma-Aldrich), following the manufacturer's recommendations.  
136 Purified DNA was used as a template to amplify a segment of the 16S rRNA gene by  
137 the PCR technique using the universal prokaryotic primers S-D-Bact-0008-a-S-20  
138 (27F) (5'-AGAGTTTGATCCTGGCTCAG-3') and S-\*-Univ-1492R-b-A-21 (1492R)  
139 (5'-GGTTACCTTGTTACGACTT-3'). For the amplified ribosomal DNA restriction  
140 analysis (**ARDRA**), amplicons were purified through GenElute PCR Clean-Up  
141 columns (Sigma-Aldrich), digested with HaeIII and HhaI restriction enzymes  
142 (Invitrogen, Pasley, UK) and electrophoresed in agarose gels. Gels were stained with  
143 ethidium bromide (0.5 mg/mL) and photographed under UV light. Representative  
144 amplicons of the different ARDRA profiles were sequenced. Sequencing was  
145 accomplished in an ABI 373 DNA sequencer (Applied Biosystems, Carlsbad, CA,  
146 USA). On average, 850 bp of sequence were obtained, which were compared to those  
147 deposited in the GenBank database using the BLAST program

148 (<http://www.ncbi.nlm.nih.gov/BLAST/>). Following the criterion applied by Palys et  
149 al. (1997), sequences with a percentage of identity of 98% or higher to those in  
150 databases were allocated to the same species.

### 151 *Molecular typing analyses*

152 In order to exclude replicates, LAB isolates were grouped by both repetitive  
153 extragenic palindromic PCR (**rep-PCR**), using the primer BOXA2R (5'-  
154 ACGTGGTTTGAAGAGATTTTCG-3'), as reported by Koeuth et al. (1995), and  
155 random amplification of polymorphic DNA (**RAPD**) with primer M13 (5'-  
156 GAGGGTGGCGTTCT-3'), as reported by Rossetti and Giraffa (2005). Banding  
157 patterns were examined with the Bionumerics 6.5 software program (Applied Maths,  
158 Belgium) using Dice's coefficient. Cluster analyses of composite data obtained with  
159 rep-PCR and RAPD were achieved using the unweighted pair group method with  
160 arithmetic averages (**UPGMA**).

### 161 *Antimicrobial activity*

162 *Pathogen inhibition.* The capability of the strains to inhibit a group of food-borne  
163 pathogens was determined using an agar spot test as described by Ripamonti et al.  
164 (2011). Overnight test cultures were spotted (2 µL) on the surface of modified MRS  
165 agar (without ammonium citrate and sodium acetate) and incubated anaerobically for  
166 24 h at 30°C. Cells were then inactivated with chloroform for 30 min. *Escherichia*  
167 *coli* ATCC 25922, *Salmonella enterica* var. Enteritidis ATCC 13076, *Staphylococcus*  
168 *aureus* ATCC 25923, and *Listeria monocytogenes* ATCC 15313 were used as  
169 indicators. A 100 µL volume of an overnight culture of each indicator was mixed with  
170 10 mL of Brain Heart Infusion (**BHI**; Difco) soft agar (0.7%), and poured onto MRS  
171 agar plates. These were incubated aerobically at 37°C for 24 h. *Lactobacillus*  
172 *acidophilus* ATCC 4356 was used as a negative control. Inhibition but not clear-cut

173 halo or less than 1mm was recorded as (+/-), a clear zone of growth inhibition around  
174 spots bigger than 1 mm was scored as positive (+), meanwhile an inhibition zone  
175 between 2 and 5 mm surrounding the colony was recorded as (++)).

176 **Bacteriocin production.** The production of bacteriocin-like inhibitory substances  
177 (BLIS) was successively examined using an agar spot test and a well-diffusion assay.  
178 *Lactobacillus sakei* CECT 906 and *Lactococcus lactis* IL 1403, two well-recognized  
179 bacteriocin-susceptible strains (Alegria et al., 2010), and *Listeria monocytogenes*  
180 ATCC 15313 were used as indicators. Overnight cultures were spotted on the surface  
181 of M17 and MRS agar plates (0.2% glucose), incubated for 24 h at 30°C for  
182 lactococci and leuconostoc strains, and at 37°C for lactobacilli, and inactivated as  
183 described previously with chloroform. Spots were covered with 10 mL of soft agar  
184 (0.75%) inoculated with the indicators and incubated under the required conditions.

185 Positive cultures were tested by a well-diffusion assay. Briefly, 20 mL of agar  
186 medium at 45°C were vigorously mixed with 200 µL of an overnight culture of each  
187 indicator and poured into Petri dishes. Supernatants from overnight cultures of the test  
188 strains were neutralized to pH 6.5-7.0 with NaOH 0.1 M, centrifuged at 12,000 g for 5  
189 min, and filter-sterilized through a 0.20 µm pore membrane (Millipore, Bedford, MA,  
190 USA). 50 µL aliquots of each supernatant were placed in a well excavated in the agar.  
191 To allow the diffusion of the supernatant into the agar, plates were maintained at 4°C  
192 for 1 h before incubation. Inhibition of the indicators was evaluated after incubation at  
193 37°C for 24 h.

194 To investigate the proteinaceous nature of the BLIS, supernatants were tested in  
195 the vicinity of wells filled with 50 µL of a solution of either proteinase K or pronase  
196 (each at a concentration of 20 mg/mL). After incubation, plates were examined to  
197 judge whether the inhibitory substance was sensitive to proteolysis. *Lactococcus*



198 *lactis* 1A6, a nisin producer strain (Alegria et al., 2010) was used as control. Tests  
199 were performed in duplicate.

#### 200 *Antioxidative activity*

201 **Sample preparation for the antioxidative assays.** Overnight cultures in MRS broth  
202 were harvested by centrifugation at 4°C for 10 min, washing with isotonic saline  
203 solution (0.85%) at 4°C and suspended in phosphate buffer with 1mM EDTA, pH 7.5.  
204 The suspension was adjusted to an OD<sub>600</sub> = 1.0. In order to obtain the cell extracts,  
205 cells were disrupted in a Cell disruptor (Constant Systems, Daventry, UK) and  
206 deposited immediately in an ice-bath. The extracts were then centrifuged at 10,000 x  
207 g at 4°C for 10 min to eliminate cell debris.

208 **Total antioxidative activity (TAA).** In order to evaluate the TAA of the strains, the  
209 linolenic acid test (**LA test**) was used as described by Kullisaar et al. (2002), using 45  
210 µL of the samples (lysate or whole bacterial cells). The absorbance at 534 nm was  
211 measured on a UV-Vis Spectrophotometer (Hitachi High-Technologies, Tokyo,  
212 Japan) and the percentage of TAA of the samples was expressed as  $[1 - (A_s/A_c)] \times$   
213  $100$ ], where:  $A_s$  is the absorbance in the presence of the sample and  $A_c$  is the  
214 absorbance of the control without sample. Intact cells and cell lysates were assayed in  
215 triplicate.

216 **Glutathione assay.** Reduced and oxidized glutathione and the glutathione redox status  
217 were evaluated using cell-free extracts and the GSH/GSSG Ratio Assay kit  
218 (Millipore, Billerica, MA, USA) following the manufacturer's instructions. The  
219 glutathione content was quantified on the basis of a standard curve generated with  
220 known amounts of glutathione. The reduced glutathione (**GSH**) content was  
221 calculated as the difference between the total glutathione (**tGSH**) and the oxidized

222 glutathione (**GSSG**). The glutathione redox ratio was expressed as GSH/GSSG.  
223 *Escherichia coli* CECT 515 was used as a positive control (Masip et al., 2006).

#### 224 ***Adhesion assay***

225 The epithelial intestinal cell line Caco-2 purchased from the European Collection  
226 of Cell Culture (ECACC 86010202) was used to assess the adhesion ability of  
227 selected strains. The culture and maintenance of the cell line were carried out  
228 following standard procedures (Sánchez et al., 2010) using DMEM medium  
229 supplemented with 20% fetal bovine serum, non-essential aminoacid solution and a  
230 mixture of antibiotics (50 µg/mL penicillin-streptomycin, 50 µg/mL gentamicin and  
231 1.25 µg/mL amphotericin B) (all reagents from Sigma-Aldrich). The cell line was  
232 used after reaching the confluent-differentiated monolayer state ( $13 \pm 1$  day). The  
233 strain *Lactobacillus rhamnosus* LMG 18243 (also known as *Lb. rhamnosus* GG) was  
234 used as a reference control for adherence.

235 Lactobacilli strains, grown overnight in 10 mL MRS under standard conditions,  
236 were harvested by centrifugation, washed twice in Dulbecco's PBS solution (Sigma-  
237 Aldrich) and suspended in supplemented-DMEM media without antibiotics, at a  
238 concentration of approximately  $10^8$  cfu/mL. To remove antibiotics from the cells,  
239 monolayers were washed twice in Dulbecco's PBS. Subsequently, the bacterial  
240 suspensions were added at a bacteria:eukaryotic cell ratio of 10:1, and incubated for 1  
241 h at 37°C in a 5% CO<sub>2</sub> atmosphere. Afterwards, wells were gently washed three times  
242 with Dulbecco's PBS buffer to remove non-adhered bacteria. Monolayers were  
243 disrupted with an EDTA-trypsin solution (Sigma-Aldrich), and the attached bacteria  
244 were counted by plating in MRS agar. Adhesion was expressed as the percentage of  
245 bacteria adhered with respect to total number of bacteria added. Experiments were

246 carried out using two independent Caco-2 plates (two consecutive passes) and in each  
247 plate bacterial strains were analyzed by duplicate.

#### 248 *Safety assessment*

249 ***Haemolysin production.*** Haemolysin production was analyzed on Columbia agar  
250 plates containing 5% sheep blood (bioMérieux, Montalieu-Vercieu, France). The  
251 presence of  $\beta$ - or  $\alpha$ -haemolysis is indicated by the formation of clear or greenish  
252 zones around the colonies, respectively.

253 ***Antibiotic resistance.*** The minimum inhibitory concentration (**MIC**) of a series of  
254 antibiotics was assayed on the selected strains by microdilution in VetMIC plates for  
255 LAB (SVA, Uppsala, Sweden), following the manufacturer's recommendations.  
256 Colonies grown on LSM (Klare et al., 2005) agar plates were suspended in 5 mL of  
257 sterile saline solution (0.9%) to obtain a density corresponding to McFarland standard  
258 1. Suspensions were further diluted 1:1000 in LSM. One hundred  $\mu$ L of this dilution  
259 were added to each well of the VetMIC plate. The plates were incubated at 37°C for  
260 48 h. MICs were defined as the lowest antibiotic concentration at which no visual  
261 growth was observed.

262 ***Enzyme activities.*** Enzyme activities were measured by the commercial, semi  
263 quantitative API-ZYM system (bioMérieux) following the manufacturer's  
264 recommendations. In short, 65  $\mu$ L of a cell suspension corresponding to McFarland  
265 standard 5 were inoculated in each well of the API-ZYM strips. Enzyme activities  
266 were evaluated after 4 h of incubation in anaerobiosis at 37°C. Enzyme activities were  
267 recorded from 0 (no activity) to 5 ( $\geq$  40 nmols of product released) with the API-  
268 ZYM colour reaction chart.

#### 269 *Statistical analyses*

270 Statistical comparisons for both the adhesion and antioxidative tests were  
271 performed using the Statistica software package for Windows version 7.0 (Statsoft,  
272 Tulsa, OK, USA). Significant differences between treatments were tested by the  
273 analysis of variance test (one-way ANOVA), followed by a comparison between  
274 means using Fisher's least significance difference (**LSD**) method, with levels of  
275 significance set at  $P < 0.05$ .

## 276 **RESULTS**

### 277 ***LAB screening for pH and bile-salt tolerance***

278 Thirty seven out of the 150 tested LAB isolates were able to grow at pH 3.0 during  
279 3 h of incubation. However, the growth in these conditions was not comparable to that  
280 in conventional MRS (pH 6.5) with reductions in counts between 2 to 3 logarithmic  
281 units as compared to controls. These 37 isolates were tested by a plate assay for  
282 resistance to different bile concentrations ranging from 0.3 to 2%, and by tolerance in  
283 liquid containing 0.3% of Oxgall. In the latter medium, a lag time (LT) ranging from  
284 0.5 to 4 h was observed for 34 isolates (Table 1); these were considered to be bile  
285 tolerant. In contrast, three LAB isolates presented an LT > 9 h; these were considered  
286 bile susceptible.

287 As a result of the bile plate assay, 34 isolates grew in 0.3%, 25 grew in 0.5%, 13 in  
288 1%, and eight in 2% (Table 1).

### 289 ***LAB identification***

290 Among the 34 isolates four different representative ARDRA profiles were  
291 observed with the HaeIII and HhaI restriction enzymes (data not shown).  
292 Representative 16S rDNA amplicons of each of the different profiles were selected  
293 for sequencing. Sequence comparisons showed a homology higher than 98% to four  
294 different LAB species. Therefore, the 34 isolates were identified as follow;

295 *Leuconostoc mesenteroides* (18), *Lactococcus lactis* subsp. *cremoris* (8),  
296 *Lactobacillus paracasei* (5), and *Lactococcus lactis* subsp. *lactis* (3).

### 297 ***LAB Typing***

298 LAB isolate typing was performed by a combination of rep-PCR and RAPD  
299 techniques. Using a 90% similarity as threshold (Fig. 1), 32 different strains (four *Lb.*  
300 *paracasei*, ten *Lc. lactis* and 18 *Leu. mesenteroides*) were considered. These were all  
301 subjected to further analyses.

### 302 ***Antimicrobial properties***

303 ***Antagonistic activity against pathogens.*** Pathogens were inhibited by most strains in  
304 the agar spot test (Table 2). *Listeria monocytogenes*, *Escherichia coli* and *Salmonella*  
305 *enterica* were inhibited by 23, 22, and 20 strains, respectively. In contrast,  
306 *Staphylococcus aureus* was inhibited by only seven strains. Pathogen inhibition,  
307 however, was not confirmed by the agar well-diffusion assay, with the exception of *L.*  
308 *monocytogenes*, that was inhibited by four strains after neutralization of the cell-free  
309 supernatants (see below).

310 ***Bacteriocin-like inhibitory substances production.*** *Lb. sakei* CECT 906 was  
311 inhibited by four strains and *Lc. lactis* IL 1403 by 12 strains (Table 2) in the agar spot  
312 assay. The isolates demonstrating antibacterial activity against any of the indicators  
313 were subsequently subjected to the well-diffusion assay. None of the *Leuconostoc*  
314 strains showed inhibition against indicators in this assay. *Lc. lactis* IL 1403 was  
315 inhibited by three lactococci strains (MRS26, M171 and MRS52). Both *L.*  
316 *monocytogenes* ATCC 15313 and *Lb. sakei* CECT 906 was inhibited by the three  
317 above mentioned lactococci strains and one *Lb. paracasei* (MRS55) strain. The  
318 proteinaceous nature of the BLIS produced by these four strains was confirmed by  
319 proteinase treatment of the cell-free supernatants.

### 320 ***Antioxidative activity***

321 According to Hutt et al. (2006) LAB strains with a TAA value > 20% are  
322 considered to have antioxidative activity. Three of the LAB strains from kefir grains  
323 (two *Lb. paracasei*; MRS 59 and M1743, and one lactococci strain; MRS 52) showed  
324 percentages above this value in either intact cells or lysate supernatants (Table 3). All  
325 other strains showed mean TAA values below 15% (data not shown), except for two  
326 other lactobacilli strains (MRS55 and MRN4), which showed a TAA between 15 and  
327 20% (Table 3).

328 The three LAB strains that showed higher values in the TAA test ( $P < 0.05$ ) were  
329 further analyzed by the glutathione assay (Table 3). The total glutathione content  
330 values (tGSH) found for the LAB strains were lower than the positive control (*E. coli*)  
331 ( $P < 0.05$ ). However the calculated glutathione redox ratio (GSSG/GSH), used to  
332 investigate oxidative stress, was similar for all the strains, except for the *Lb.*  
333 *paracasei* M1743 strain, in which the oxidized glutathione (GSSG) content was not  
334 detectable and, consequently, its GSH/GSSG redox ratio could not be calculated.

335 Based on the results obtained in the antimicrobial and antioxidative tests, three *Lb.*  
336 *paracasei* strains (MRS55, MRS59 and M1743) were considered as presenting  
337 probiotic potential and were selected for further analyses.

### 338 ***Adhesion capability***

339 The results of the adhesion assay for the three selected strains are depicted in  
340 Figure 2. Adhesion percentages ranged from 0.9 to 9%. The adhesion level of the  
341 MRS59 strain was similar to that of the reference strain GG, whereas those of M1743  
342 and MRS 55 were lower ( $P < 0.05$ ).

### 343 ***Enzymatic activities and haemolysin production***

344 Undesirable activities, such as trypsin,  $\alpha$ -chymotrypsin, and  $\beta$ -glucuronidase  
345 activities, were not detected in any of the selected strains. In addition, none of the  
346 three strains showed hemolytic activity under the assay conditions.

#### 347 *Antibiotic resistance*

348 The selected lactobacilli strains were susceptible to all the analyzed antimicrobial  
349 agents (including tetracycline, erythromycin, clindamycin, ampicillin and  
350 aminoglycosides) with the exception of vancomycin, for which an intrinsic resistance  
351 was observed. The chloramphenicol MIC for MRS55 and M1743 strains was only one  
352 dilution higher (8  $\mu$ g/mL) than the microbiological breakpoint defined by the EFSA  
353 (4  $\mu$ g/mL), which is within the normal acceptable variation around the means (EFSA,  
354 2012).

## 355 **DISCUSSION**

356 Beyond their technological function, there is currently an increasing demand for  
357 new LAB strain probiotic candidates (Ayeni et al., 2011; Argyri et al., 2013). The  
358 complex microbiota of kefir, a traditional beverage endowed with several health  
359 benefits (Leite et al., 2013a), could be a source for obtaining novel probiotic strains  
360 (Santos et al., 2003; Kumura et al., 2004).

361 In the present study, LAB were isolated from four kefir grain samples, identified  
362 and typed by molecular methods, and characterized *in vitro* for recognized probiosis  
363 properties, such as acidity and bile tolerance and antimicrobial and antioxidant  
364 activities, key features to consider bacterial strains as probiotics. The secretion of  
365 gastric acid and transit through stomach constitutes a primary defence mechanism that  
366 all ingested microorganisms must overcome, including probiotics (Gueimonde and  
367 Salminen, 2006). LAB isolates from kefir grains were screened and selected for their  
368 resistance and survival in an acidic environment, as well as for their growth in the

369 presence of 0.3% bile salts, a similar concentration to that present in the small  
370 intestine (Vinderola et al., 2008). Though there is no scientific consensus on the pH  
371 and bile concentration to which probiotic strains should be tolerant to (Zago et al.,  
372 2011), based on the results, the lactobacilli were able to grow in higher bile  
373 concentrations (1%). Similar results have been previously reported by other authors  
374 analyzing LAB strains from different environments (Delgado et al., 2007; Vinderola  
375 et al., 2008; Zago et al., 2011; Ramos et al., 2013).

376 Molecular typing showed a rather high genetic heterogeneity among the LAB  
377 isolates from the four kefir grains as judged by the large number of different profiles  
378 obtained.

379 Some of these LAB strains exhibited antimicrobial activity against pathogens, and  
380 four of them produced BLIS, which might provide advantage in competing either in a  
381 food product or in the gut (Servin, 2004; Vinderola et al., 2008). Moreover, we  
382 observed one *Lactococcus* BLIS-producing strain, as well as, two *Lb. paracasei*,  
383 showed an antioxidative activity higher than those of other tested LAB strains ( $P <$   
384 0.05), indicating they may aid in protecting cells from oxidative damage (Lin and  
385 Chang, 2000; Zhang et al., 2010). In particular, the lactococcal strain showed higher  
386 TAA in intact cells, meanwhile in the *Lb. paracasei* strains, the antioxidative activity  
387 was more relevant in cell extracts indicating that this activity might be also relevant in  
388 case of bacterial lysis into the gastrointestinal tract and release of the intracellular  
389 content. Furthermore, reduced glutathione (GSH), an important component of the cell  
390 defence system against oxidative stress (Masip et al., 2006), was detected for all the  
391 LAB strains that showed TAA values  $> 20\%$ . However the obtained values suggest  
392 that the antioxidative effect displayed by some of these strains could be attained by  
393 means of other mechanisms different from glutathione protection, such as enzymatic



394 antioxidants. The antioxidative activities of LAB strains have been under  
395 investigation in other studies (Kullisaar et al., 2002; Li et al., 2012; Chen et al., 2014).  
396 This protective property may be useful as a defence mechanism in the intestinal  
397 microbial ecosystem.

398 Strains belonging to the *Lactobacillus* genus are commonly used as probiotics  
399 (FAO/WHO, 2006; Gueimonde and Salminen, 2006; Zago et al., 2011). Three *Lb.*  
400 *paracasei* strains were considered as appropriate probiotic candidates and selected for  
401 further characterization of desirable and undesirable probiotic-related properties.

402 The capacity to adhere to the intestinal mucosa is an important property for  
403 probiotic strains, since they should, at least transiently, colonize, the host gut  
404 (FAO/WHO, 2006). The human colon adenocarcinoma cell line Caco-2 is widely  
405 accepted as a model for assessing the adhesion ability of probiotic candidates  
406 (Gueimonde and Salminen, 2006; Ayeni et al., 2011). One *Lb. paracasei* strain in this  
407 study (MRS59) showed similar adhesion values than the recognized probiotic strain  
408 *Lb. rhamnosus* GG, suggesting they may well be good *in vivo* colonizers.

409 None of these lactobacilli showed  $\beta$ -glucuronidase activity, which may have  
410 negative effects in the colon and has been considered a carcinogenic enzyme  
411 (Monteagudo-Mera et al., 2011). In contrast, all three strains produced  $\beta$ -  
412 galactosidase, a beneficial enzyme considering both probiotic and technological  
413 aspects, supporting the reduction of lactose intolerance as well as milk acidification  
414 (Monteagudo-Mera et al., 2011). These strains also presented  $\alpha$ -glucosidase and  $\beta$ -  
415 glucosidase activity, which could contribute to polysaccharide digestion (Papamanoli  
416 et al., 2003). The presence of glycosidase activities in food cultures seems to have an  
417 impact on sensory properties, since flavour is often linked to sugar metabolism  
418 (Papamanoli et al., 2003; Mesas et al., 2011).

419 In summary, 32 different LAB strains isolated from kefir grains showing good  
420 survival under normal gastrointestinal conditions were evaluated *in vitro* for  
421 antimicrobial and antioxidative activities in this study. Among the analyzed strains,  
422 three *Lb. paracasei* strains were further selected. The presence of harmful enzymatic  
423 activities and atypical antibiotic resistances among the selected strains were  
424 discarded. Based on a long history of human consumption, *Lb. paracasei*, like many  
425 other LAB species, is granted a Qualified Presumption of Safety (QPS) status (EFSA,  
426 2011), allowing unrestricted application in food and feed, provided there is an  
427 absence of antibiotic resistance. Among the three selected strains, *Lb. paracasei*  
428 MRS59 showed the highest number of *in vitro* probiosis properties; consequently, it  
429 was considered as the most appropriate kefir-derived candidate to be used as a  
430 probiotic. Further *in vivo* studies should be also performed to confirm its potential  
431 beneficial effects.

#### 432 ACKNOWLEDGEMENTS

433 This study was supported by FAPERJ, CAPES Foundation (process number PDEE  
434 5019109) and funds from the Spanish Ministry of Science and Innovation (MICINN)  
435 (reference AGL2011-24300 and AGL2012-33278). S. Delgado was supported by a  
436 research contract from MICINN under the Juan de la Cierva Program (reference JCI-  
437 2008-02391).

#### 438 REFERENCES

- 439 Alegria, A., S. Delgado, C. Roces, B. Lopez, and B. Mayo. 2010. Bacteriocins  
440 produced by wild *Lactococcus lactis* strains isolated from traditional, starter-free  
441 cheeses made of raw milk. *Int. J. Food Microbiol.* 143(1-2):61-66.
- 442 Argyri, A. A., G. Zoumpopoulou, K.-A. G. Karatzas, E. Tsakalidou, G.-J. E. Nychas,  
443 E. Z. Panagou, and C. C. Tassou. 2013. Selection of potential probiotic lactic acid  
444 bacteria from fermented olives by *in vitro* tests. *Food Microbiol.* 33(2):282-291.
- 445 Ayeni, F. A., B. Sanchez, B. A. Adeniyi, C. G. de Los Reyes-Gavilan, A. Margolles,  
446 and P. Ruas-Madiedo. 2011. Evaluation of the functional potential of *Weissella*  
447 and *Lactobacillus* isolates obtained from Nigerian traditional fermented foods and  
448 cow's intestine. *Int. J. Food Microbiol.* 147(2):97-104.

449 Chen, P., Q. Zhang, H. Dang, X. Liu, F. Tian, J. Zhao, Y. Chen, H. Zhang, and W.  
450 Chen. 2014. Screening for potential new probiotic based on probiotic properties  
451 and  $\alpha$ -glucosidase inhibitory activity. *Food Control* 35(1):65-72.

452 Chifiriuc, M. C., A. B. Cioaca, and V. Lazar. 2011. In vitro assay of the antimicrobial  
453 activity of kephir against bacterial and fungal strains. *Anaerobe* 17(6):433-435.

454 Delgado, S., E. O'Sullivan, G. Fitzgerald, and B. Mayo. 2007. Subtractive screening  
455 for probiotic properties of *Lactobacillus* species from the human gastrointestinal  
456 tract in the search for new probiotics. *J. Food Sci.* 72(8):M310-315.

457 EFSA. 2011. EFSA Panel on Biological Hazards (BIOHAZ). Scientific Opinion on  
458 the maintenance of the list of QPS biological agents intentionally added to food  
459 and feed (2011 update) 9(12):82.

460 EFSA. 2012. EFSA Panel on Additives and Products or Substances used in Animal  
461 Feed (FEEDAP): Guidance on the assesment of bacterial susceptibility to  
462 antimicrobials of human and veterinary importance. *EFSA Journal* 10(6):10.

463 FAO/WHO. 2006. Probiotic in foods. Health and nutritional properties and guidelines  
464 for evaluation. Vol. 85. FAO Food and Nutrition Paper, Rome.

465 Golowczyc, M. A., M. J. Gugliada, A. Hollmann, L. Delfederico, G. L. Garrote, A. G.  
466 Abraham, L. Semorile, and G. De Antoni. 2008. Characterization of  
467 homofermentative lactobacilli isolated from kefir grains: potential use as  
468 probiotic. *J Dairy Res.* 75(2):211-217.

469 Gueimonde, M. and S. Salminen. 2006. New methods for selecting and evaluating  
470 probiotics. *Dig. Liver Dis.* 38:S242-S247.

471 Guo, Z., J. Wang, L. Yan, W. Chen, X.-m. Liu, and H.-p. Zhang. 2009. In vitro  
472 comparison of probiotic properties of *Lactobacillus casei* Zhang, a potential new  
473 probiotic, with selected probiotic strains. *LWT - Food Sci. Technol.* 42(10):1640-  
474 1646.

475 Hertzler, S. R. and S. M. Clancy. 2003. Kefir improves lactose digestion and  
476 tolerance in adults with lactose maldigestion. *J. Am. Diet. Assoc.* 103(5):582-587.

477 Hong, W.-S., H.-C. Chen, Y.-P. Chen, and M.-J. Chen. 2009. Effects of kefir  
478 supernatant and lactic acid bacteria isolated from kefir grain on cytokine  
479 production by macrophage. *Int. Dairy J.* 19(4):244-251.

480 Hutt, P., J. Shchepetova, K. Loivukene, T. Kullisaar, and M. Mikelsaar. 2006.  
481 Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero-  
482 and uropathogens. *J. Appl. Microbiol.* 100(6):1324-1332.

483 Klare, I., C. Konstabel, S. Muller-Bertling, R. Reissbrodt, G. Huys, M. Vancanneyt, J.  
484 Swings, H. Goossens, and W. Witte. 2005. Evaluation of new broth media for  
485 microdilution antibiotic susceptibility testing of *Lactobacilli*, *Pediococci*,  
486 *Lactococci*, and *Bifidobacteria*. *Appl. Environ. Microbiol.* 71(12):8982-8986.

487 Koeuth, T., J. Versalovic, and J. R. Lupski. 1995. Differential subsequence  
488 conservation of interspersed repetitive *Streptococcus pneumoniae* BOX elements  
489 in diverse bacteria. *Genome Res.* 5(4):408-418.

490 Kullisaar, T., M. Zilmer, M. Mikelsaar, T. Vihalemm, H. Annuk, C. Kairane, and A.  
491 Kilk. 2002. Two antioxidative lactobacilli strains as promising probiotics. *Int. J.*  
492 *Food Microbiol.* 72(3):215-224.

493 Kumura, H., Y. Tanoue, M. Tsukahara, T. Tanaka, and K. Shimazaki. 2004.  
494 Screening of dairy yeast strains for probiotic applications. *J. Dairy Sci.*  
495 87(12):4050-4056.

496 Leite, A. M. O., B. Mayo, C. T. C. C. Rachid, R. S. Peixoto, J. T. Silva, V. M. F.  
497 Paschoalin, and S. Delgado. 2012. Assessment of the microbial diversity of

498 Brazilian kefir grains by PCR-DGGE and pyrosequencing analysis. *Food*  
499 *Microbiol.* 31(2):215-221.

500 Leite, A. M. O., M. A. Miguel, R. S. Peixoto, A. S. Rosado, J. T. Silva, and V. M.  
501 Paschoalin. 2013a. Microbiological, technological and therapeutic properties of  
502 kefir: a natural probiotic beverage. *Braz. J. Microbiol.* 44(2):341-349.

503 Leite, A. M. O., D. C. Leite, E. M. Del Aguila, T. S. Alvares, R. S. Peixoto, M. A.  
504 Miguel, J. T. Silva, and V. M. Paschoalin. 2013b. Microbiological and chemical  
505 characteristics of Brazilian kefir during fermentation and storage processes. *J.*  
506 *Dairy Sci.* 96(7):4149-4159.

507 Li, S., Y. Zhao, L. Zhang, X. Zhang, L. Huang, D. Li, C. Niu, Z. Yang, and Q. Wang.  
508 2012. Antioxidant activity of *Lactobacillus plantarum* strains isolated from  
509 traditional Chinese fermented foods. *Food Chem.* 135(3):1914-1919.

510 Lin, M. Y. and F. J. Chang. 2000. Antioxidative effect of intestinal bacteria  
511 *Bifidobacterium longum* ATCC 15708 and *Lactobacillus acidophilus* ATCC 4356.  
512 *Dig. Dis. Sci.* 45( 8):1617-1622.

513 Liu, J. R., S. Y. Wang, M. J. Chen, H. L. Chen, P. Y. Yueh, and C. W. Lin. 2006.  
514 Hypocholesterolaemic effects of milk-kefir and soyamilk-kefir in cholesterol-fed  
515 hamsters. *Br. J. Nutr.* 95(5):939-946.

516 Masip, L., K. Veeravalli, and G. Georgiou. 2006. The many faces of glutathione in  
517 bacteria. *Antioxid. Redox Signal.* 8(5-6):753-762.

518 Mesas, J. M., M. C. Rodriguez, and M. T. Alegre. 2011. Characterization of lactic  
519 acid bacteria from musts and wines of three consecutive vintages of Ribeira Sacra.  
520 *Lett. Appl. Microbiol.* 52(3):258-268.

521 Monteagudo-Mera, A., I. Caro, L. B. Rodriguez-Aparicio, J. Rúa, M. A. Ferrero, and  
522 M. R. Garcia-Armesto. 2011. Characterization of certain bacterial strains for  
523 potential use as starter or probiotic cultures in dairy products. *J. Food Prot.*  
524 74(8):1379-1386.

525 Nielsen, B., G. C. Gurakan, and G. Unlu. 2014. Kefir: a multifaceted fermented dairy  
526 product. *Probiotics and antimicrobial proteins* 6(3-4):123-135.

527 Nishida, S., A. Michinaka, K. Nakashima, H. Iino, and T. Fujii. 2008. Evaluation of  
528 the probiotic potential of *Lactobacillus paracasei* KW3110 based on in vitro tests  
529 and oral administration tests in healthy adults. *J. Gen. Appl. Microbiol.* 54(5):267-  
530 276.

531 Palys, T., L. K. Nakamura, and F. M. Cohan. 1997. Discovery and classification of  
532 ecological diversity in the bacterial world: the role of DNA sequence data. *Int. J.*  
533 *Syst. Bacteriol.* 47(4):1145-1156.

534 Papamanoli, E., N. Tzanetakis, E. Litopoulou-Tzanetaki, and P. Kotzekidou. 2003.  
535 Characterization of lactic acid bacteria isolated from a Greek dry-fermented  
536 sausage in respect of their technological and probiotic properties. *Meat Sci.*  
537 65(2):859-867.

538 Ramos, C. L., L. Thorsen, R. F. Schwan, and L. Jespersen. 2013. Strain-specific  
539 probiotics properties of *Lactobacillus fermentum*, *Lactobacillus plantarum* and  
540 *Lactobacillus brevis* isolates from Brazilian food products. *Food Microbiol.*  
541 36(1):22-29.

542 Ripamonti, B., A. Agazzi, C. Bersani, P. De Dea, C. Pecorini, S. Pirani, R. Rebutti,  
543 G. Savoini, S. Stella, A. Stenico, E. Tirloni, and C. Domeneghini. 2011. Screening  
544 of species-specific lactic acid bacteria for veal calves multi-strain probiotic  
545 adjuncts. *Anaerobe* 17(3):97-105.

546 Rodrigues, K. L., L. R. Caputo, J. C. Carvalho, J. Evangelista, and J. M. Schneedorf.  
547 2005. Antimicrobial and healing activity of kefir and kefiran extract. *Int. J.*  
548 *Antimicrob. Agents* 25(5):404-408.

549 Rossetti, L. and G. Giraffa. 2005. Rapid identification of dairy lactic acid bacteria by  
550 M13-generated, RAPD-PCR fingerprint databases. *J. Microbiol. Methods*  
551 63(2):135-144.

552 Sánchez, B., M. Fernández-García, A. Margolles, C. G. de los Reyes-Gavilán, and P.  
553 Ruas-Madiedo. 2010. Technological and probiotic selection criteria of a bile-  
554 adapted *Bifidobacterium animalis* subsp. *lactis* strain. *Int. Dairy J.* 20(11):800-  
555 805.

556 Santos, A., M. San Mauro, A. Sanchez, J. M. Torres, and D. Marquina. 2003. The  
557 Antimicrobial Properties of Different Strains of *Lactobacillus* spp. Isolated from  
558 Kefir. *Syst. Appl. Microbiol.* 26(3):434-437.

559 Schmidt, P., A. Vass, and S. Szakaly. 1984. Effect of fermented milk diets on  
560 regeneration of the rat liver. *Acta Med. Hung.* 41(2-3):163-169.

561 Servin, A. L. 2004. Antagonistic activities of lactobacilli and bifidobacteria against  
562 microbial pathogens. *FEMS Microbiol. Rev.* 28(4):405-440.

563 Urdaneta, E., J. Barrenetxe, P. Aranguren, A. Irigoyen, F. Marzo, and F. C. Ibáñez.  
564 2007. Intestinal beneficial effects of kefir-supplemented diet in rats. *Nutr. Res.*  
565 27(10):653-658.

566 Vinderola, G., B. Capellini, F. Villarreal, V. Suárez, A. Quiberoni, and J. Reinheimer.  
567 2008. Usefulness of a set of simple in vitro tests for the screening and  
568 identification of probiotic candidate strains for dairy use. *LWT - Food Sci.*  
569 *Technol.* 41(9):1678-1688.

570 Zago, M., M. E. Fornasari, D. Carminati, P. Burns, V. Suárez, G. Vinderola, J.  
571 Reinheimer, and G. Giraffa. 2011. Characterization and probiotic potential of  
572 *Lactobacillus plantarum* strains isolated from cheeses. *Food Microbiol.*  
573 28(5):1033-1040.

574 Zanirati, D.F. M. Jr. Abatemarco, S. H. Sandes, J. R. Nicoli, Á. C. Nunes, and E.  
575 Neumann. 2014. Selection of lactic acid bacteria from Brazilian kefir grains for  
576 potential use as starter or probiotic cultures. *Anaerobe.* 24:32C:70-76.

577 Zhang, Y., R. Du, L. Wang, and H. Zhang. 2010. The antioxidative effects of  
578 probiotic *Lactobacillus casei* Zhang on the hyperlipidemic rats. *Eur Food Res*  
579 *Technol.* 231(1):151-158.

580  
581

582 **Table 1.** Bile resistance of 32 identified and typed LAB isolated from kefir grains

Strain	Identification	Origin	Bile assay				
			Lag time (h) 0.3% bile	Growth plate <sup>1</sup>			
				0.3% bile	0.5% bile	1% bile	2% bile
MRS17		AR	2	+	+	+	+
M1711B		AR	3	+	+	-	-
MRS26	<i>Lactococcus lactis</i> subsp. <i>cremoris</i>	AR	1.5	+	+	-	-
MRS47		AD	3	+	-	-	-
M1732		AR	1	+	-	-	-
M1734		AR	2	+	+	-	-
M171		AR	1	+	+	-	-
MR2	<i>Lactococcus lactis</i> subsp. <i>lactis</i>	AV	1	+	+	+	+
MRS52		AD	1	+	+	-	-
MRN3		AV	4	+	+	-	-
MRN4	<i>Lactobacillus paracasei</i>	AR	1	+	+	+	+
MRS59		AF	2	+	+	+	-
M1743		AF	2	+	+	+	+
MRS55		AF	3	+	+	+	-
MRS2	<i>Leuconostoc mesenteroides</i>	AR	2	+	+	-	-
GYP8		AR	3	+	+	+	-
MRS12		AR	1.5	+	+	-	-
MRS50		AD	2	+	-	-	-
MRS48		AF	3	+	-	-	-
MRS53		AF	2	+	-	-	-
MRS25		AR	2	+	+	+	+
GYP7		AR	1	+	+	+	+
MRS8		AR	2	+	+	-	-
MRS14		AR	1.5	+	+	-	-
GYP5		AR	2	+	-	-	-
MRS10		AR	4	+	+	-	-
GYP9		AR	1	+	+	+	+
GYP12		AR	0.5	+	+	+	-
M1721		AR	2.5	+	-	-	-
MRS19		AR	1.5	+	-	-	-
MRS24		AR	1	+	-	-	-
M1711A		AR	2	+	+	-	-

583  
584  
585

<sup>1</sup>Growth plate: - = no growth; + = positive growth

586 **Table 2.** Antimicrobial activity data of 32 identified and typed LAB isolated from  
 587 kefir grains

Strain	Identification	Origin	Inhibition profile						
			Spot test						
			Pathogen inhibition			Bacteriocin production			
			I <sup>1</sup>	II	III	IV	IV	V	VI
MRS17		AR	± <sup>2</sup>	++ <sup>3</sup>	- <sup>4</sup>	-	-	-	-
M1711B		AR	±	±	-	-	-	-	-
<b>MRS26*</b>	<i>Lactococcus lactis</i> subsp. <i>cremoris</i>	AR	++	-	±	++	++	++	++
MRS47		AD	++	-	-	-	-	-	-
M1732		AR	-	++	-	±	±	-	-
M1734		AR	-	++	-	±	±	-	±
<b>M171</b>		AR	++	-	±	++	++	++	++
MR2	<i>Lactococcus lactis</i> subsp. <i>lactis</i>	AV	++	-	-	++	++	-	-
<b>MRS52</b>		AD	-	-	-	++	++	++	++
MRN3		AV	++	±	-	++	++	-	-
MRN4	<i>Lactobacillus paracasei</i>	AR	±	++	-	-	-	-	++
MRS59		AF	++	++	-	++	++	-	++
M1743		AF	++	++	±	±	±	-	±
<b>MRS55</b>		AF	++	++	-	++	++	++	++
MRS2	<i>Leuconostoc mesenteroides</i>	AR	-	-	-	±	±	-	±
GYP8		AR	±	±	±	-	-	-	-
MRS12		AR	+	±	±	±	±	-	-
MRS50		AD	-	-	±	±	±	-	±
MRS48		AF	-	-	+	±	±	-	±
MRS53		AF	-	-	-	-	-	-	-
MRS25		AR	±	-	-	±	±	-	±
GYP7		AR	±	-	-	-	-	-	-
MRS8		AR	-	±	-	±	±	-	-
MRS14		AR	-	±	-	±	±	-	-
GYP5		AR	+	±	-	±	±	-	-
MRS10		AR	±	±	-	±	±	-	-
GYP9		AR	±	±	-	±	±	-	-
GYP12		AR	-	-	-	-	-	-	-
M1721		AR	±	±	-	±	±	-	-
MRS19		AR	±	±	-	±	±	-	-
MRS24		AR	±	±	-	±	±	-	-
M1711A		AR	±	±	-	-	-	-	-

588 <sup>1</sup>Indicators: I = *Escherichia coli* ATCC 25922; II = *Salmonella enterica* serovar Enteritidis ATCC 13076; III =  
 589 *Staphylococcus aureus* ATCC 25923; IV = *Listeria monocytogenes* ATCC 15313; V = *Lactobacillus sakei* CECT  
 590 906; VI = *Lactococcus lactis* IL1403.

591 <sup>2</sup>±: inhibition but no clear halo.

592 <sup>3</sup>++ : presence of a clearly defined inhibition zone surrounding the colony in the spot test or the wells containing  
 593 neutralized, cell-free supernatant.

594 <sup>4</sup>-: no inhibition.

595 \*strains in bold: producing bacteriocin-like inhibitory substances (BLIS)

596

597

598

599 **Table 3.** Data on total antioxidative activity (TAA) and glutathione determinations  
600 (total, reduced and oxidized glutathione and glutathione redox ratio) of representative  
601 LAB strains from kefir grains showing antioxidative activity

Strain	Identification	TAA test <sup>1</sup> (%)		Glutathione test <sup>2</sup> (μM)			
		Intact cells	Cell lysate	Cell lysate			
				tGSH	GSSG	GSH	GSH/GSSG
MRS52	<i>Lc. lactis</i> subsp. <i>lactis</i>	20.3 ± 3.5 <sup>a</sup>	11.8 ± 3.9 <sup>b</sup>	0.586±0.23 <sup>b</sup>	0.062±0.03 <sup>b</sup>	0.461±0.14 <sup>b</sup>	8.75±3.19 <sup>a</sup>
MRS59	<i>Lb. paracasei</i>	18.4 ± 4.1 <sup>a,c</sup>	34.1 ± 9.9 <sup>a</sup>	0.157±0.21 <sup>b</sup>	0.024±0.01 <sup>b</sup>	0.110±0.19 <sup>b</sup>	5.72 ±3.09 <sup>a</sup>
MRN4	<i>Lb. paracasei</i>	3.5 ± 2.9 <sup>b</sup>	14.7 ± 12.7 <sup>b</sup>	n.d.	n.d	n.d	n.d.
M1743	<i>Lb. paracasei</i>	22.3 ± 9.0 <sup>a</sup>	26.0 ± 4.2 <sup>a,b</sup>	0.106±0.13 <sup>b</sup>	0	0.106±0.13 <sup>b</sup>	0
MRS55	<i>Lb. paracasei</i>	10.4 ± 2.3 <sup>b,c</sup>	18.2 ± 2.1 <sup>b</sup>	n.d.	n.d.	n.d.	n.d.
CECT515 <sup>3</sup>	<i>E. coli</i>	n.d.	n.d.	2.313±0.48 <sup>a</sup>	0.31±0.04 <sup>a</sup>	1.686±0.40 <sup>a</sup>	5.33±0.67 <sup>a</sup>

602 <sup>1</sup>TAA test – Total antioxidative activity;603 <sup>2</sup>Glutathione test: tGSH = total glutathione; GSSG = oxidized glutathione; GSH = reduced glutathione; n.d. = not  
604 determined;605 <sup>3</sup> *E. coli* CECT 515 was used as positive control

606 The data are expressed as the means ± standard deviation, based on three replicates.

607 <sup>a-c</sup>Columns that do not share the same letter are statistically different according to the least significant differences  
608 (LSD) mean comparison test ( $P < 0.05$ )

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639


640




A




B



C



644 Leite 2  
645



646  
647

648 **Figure 1.** Combined dendrogram obtained from rep-PCR and RAPD-PCR profiles,  
649 using BOXA2R and M13 primers corresponding to five *Lactobacillus paracasei*  
650 strains (Panel A); eleven *Lactococcus lactis* strains (Panel B) and eighteen  
651 *Leuconostoc mesenteroides* strains (Panel C).

652 **Figure 2.** Percentage of adhesion measured as the percentage of cfu/mL adhered  
653 bacteria with respect to cfu/mL added bacteria of the three *Lactobacillus paracasei*  
654 strains to the intestinal epithelial cell line Caco-2. Columns that do not share the same  
655 letter are statistically different according to the least significant differences (LSD)  
656 mean comparison test ( $P < 0.05$ ). *Lactobacillus rhamnosus* GG was used as an  
657 adherent reference strain.

658